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According to the Central Dogma, genes in genome can be 
transcribed and translated into proteins to perform a variety 
of biological functions. Since proteins are the actual func-
tional molecules in almost all physiological processes, dis-
covering new proteins is essential to understand the nature 
of various biological phenomena. So far, the Human Ge-
nome Project and many transcriptomic analyses have de-
fined about 20300 genes that can be transcribed into mRNA. 
These genes, comprising only 2% of human genome, are 
considered as coding genes that may be translated into pro-
teins. 
Are the other 98% human genome really non-coding? Or 
there may be numerous annotation errors in human genome? 
The definite answer to these questions is to provide evi-
dence of the presence or absence of those genes at the pro-
tein level. However, the expression of proteins varies tem-
porally and spatially. Some proteins are expressed specifi-
cally in one tissue but not in another; other proteins are ex-
pressed only under specific physiological conditions. Thus, 
many proteins have not been ever detected.  
The Human Proteome Project (HPP) was therefore pro-
posed by the Human Proteome Organization (HUPO), aim-
ing at identifying all proteins encoded by coding genes and 
determining their distribution in tissues, cells, sub-cellular 
organelles, with various physiological and pathological 
phenotypes [1–3]. One important ambition of HPP is to 
identify “missing proteins” [1]. Generally, missing proteins 
refer to two classes of proteins, namely “undetected pro-
teins” and “new (novel) proteins”. Undetected proteins are 
those encoded by the coding genes but their protein evi-
dence has not been detected by current experimental tech-
nologies although they may actually exist in samples. New 
(novel) proteins are those encoded by erroneously annotated 
“non-coding genes”.  
Conventional methods to directly identify proteins in-
clude mass spectrometry and antibody-based immunologi-
cal detection. Using mass spectrometry, peptide fragments 
from a digested protein can be detected as mass spectral 
signals, which are matched to the theoretical peptide mass 
spectrum based on the protein sequence database to identify 
the protein. Currently, advanced mass spectrometry can 
identify approximately 12000 proteins in single human cells; 
the detection sensitivity can even be improved by using 
SRM/MRM technology [4,5]. However, mass spectrometry 
has its inherent limitations in protein identification, includ-
ing the requirement for the large amount of samples, low 
identification rates for low-abundance proteins and low re-
producibility from different laboratories [6,7]. Moreover, 
the physical and chemical properties of proteins also affect 
their detectability in mass spectrometry. Some proteins, 
including hydrophobic membrane proteins, structurally 
compact proteins that are resistant to enzyme digestion, and 
easily degradable proteins, are difficult to be detected. 
These problems lead to the low peptide coverage: only a 
few peptides of a certain protein are detected, although the 
protein may have been digested into many peptides.  
Complementarily, HPP proposed antibody-based detec-
tion as an alternative tool, which indeed made great pro-
gress in protein identification [1,2,8]. Nevertheless, such a 
method may encounter low-staining situation, puzzling the 
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detection of target proteins. In addition, an antibody typi-
cally recognizes a specific epitope of a protein, covering a 
limited part of the protein sequence. More importantly, a 
pre-requirement for both mass spectrometry and anti-
body-based verification is the establishment of protein se-
quence database. For those new proteins and mutants re-
sulting from single nucleotide variation (SNV) and RNA 
editing, their sequences either are absent in or differ from 
those in the database. Thus, both detection methods have 
limitation for the identification of new proteins.  
Transcriptome sequencing can provide indirect clue of 
possible coding mRNAs in cells under steady-state. It can 
also detect mRNA sequence variations and splice variants 
[4,914]. However, transcriptome sequencing still has cru-
cial drawbacks even with substantially developed next- 
generation sequencing techniques (NGS). Numerous studies 
have found untranslated mRNA species in various human 
cell lines [15–18], and these species comprise approximate-
ly 5% of the transcriptome [2,14]. Transcriptome sequenc-
ing does not distinguish the translating and untranslated 
RNA. Therefore, this strategy cannot give information to 
guide the discovery of new proteins. 
To correct the possible annotation errors in genome and 
to discover new proteins, we proposed a new strategy that 
analyzes the translating mRNA (translatome sequencing) to 
find the translating evidence of known and unknown coding 
genes [14,19]. It is known that proteins are synthesized via 
translation, therefore the translating evidence of proteins, 
obtained by translatome sequencing and sequence analysis, 
can be a sensitive method to find new proteins. This method 
purifies ribosome-nascent-chain complex (RNC) and se-
quences the mRNA in this fraction. The RNC purification is 
the key step that can be performed efficiently using sucrose 
gradient ultracentrifugation [14]. Under steady-state, protein 
species can exist only via translation, i.e., translating 
mRNAs most likely correspond to proteins. This realizes 
using sequencing technology to study proteins. 
Full-length translating mRNA sequencing (RNC-seq) 
exhibits unique advantages against traditional protein iden-
tification methods. The high sensitivity of NGS ensures 
high identification efficiency. Under normal sequencing 
throughput (10–20 million reads), it is possible to identify 
and quantify more than 14000 RNC-mRNA in RefSeq da-
tabase from single human cell lines, by using highly accu-
rate FANSe series mapping algorithm [14,19,20]. The pow-
er of quantification and identification exceeds the mass 
spectrometry considerably at low cost. NGS is independent 
of physical and chemical properties of proteins, therefore, 
translatome sequencing is easier to provide translation evi-
dence to those proteins that are difficult to be identified by 
mass spectrometry. Another advantage of translatome se-
quencing is to identify enough number of protein coding 
genes at lower starting quantity of samples and lower 
throughput. For example, the down sampling of translatome 
sequencing dataset of human hepatocarcinoma cells Hep3B 
revealed that two million reads can identify more than 
11000 genes [21]. Translatome sequencing can provide de-
finitive translation evidence of proteins and avoids the “low 
staining” problem of antibody detection. Therefore, it is 
effective to detect cell/tissue-specific expressed proteins. 
For example, we identified 750 and 2105 genes that are 
specifically expressed in human bronchial epithelial cells 
HBE and human colorectal cancer cell Caco-2 [19]. 
Taking the advantage of the high-throughput NGS, 
translatome sequencing achieves high sequence coverage. 
For mid-to-low abundance RNC-mRNAs (10–50 rpkM), 
almost 100% sequence coverage can be typically reached 
[19]. The third-generation sequencing technology is theo-
retically possible to directly sequence the full-length mRNA. 
This covering power consolidates the identification. It is 
also possible to detect any sequence variation and alterna-
tive spliced transcripts by translatome sequencing, thus de-
tecting the missing proteins effectively. 
Translatome sequencing does not rely on the database 
annotation. Therefore, conventional non-coding RNA 
(ncRNA) may be identified in the RNC-mRNA fraction. 
For example, we found 1397 genes that were annotated as 
ncRNA in RefSeq database in Caco-2 translating mRNA, 
indicating that these genes are being translated [19]. Among 
them, HMGB3P1 and ESRG are traditional ncRNAs but 
were found in the RNC-mRNA fraction in multiple human 
cell lines including HBE, A549, H1299 and Caco-2 [14,19]. 
As an example of new protein discovery, ESRG has been 
found to code HESRG protein [22,23]. 
In the HPP, HUPO suggested three resource pillars for 
human proteome studies and missing protein identification: 
mass spectrometry, bioinformatics and antibody [1]. Cur-
rently, we have proposed that translatome sequencing can 
serve as the fourth resource pillar for HPP [19]. This strate-
gy has already been applied in the collaboration work car-
ried out by Chinese HPP Consortium (JPR special issue, 
2014). We believe that translatome sequencing is an im-
portant complementary method of traditional proteomics, 
and can independently lead to discovery of new proteins 
functioning in various physiological and pathological con-
ditions.  
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